Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (5361)	1/19/1998 11:58:00 AM
From: aknahow	Respond to of 17367

Tharos, thanks. The following is not T.A but a news story on NIH opening in next few months of new BL-4 lab to study, "mutant strains of tuberculosis that have become resistant to available antibiotics and pose an alarming threat around the world-TB infects an estimated 30 million people worldwide annually and kills 3 million, about 2,000 of them in the United States." Article in L.A. Times Jan 19. While no direct relation to XOMA at present in time this may change. If the NIH did ever use Neuprex then we have the question of who owns the discoveries even if they are made.